The Specific Aim of the Molecular Diagnostics Core is to support Projects by performing assays integral to the completion of their Specific Aims. Specifically, for Project 2 we will perform FLT3-ITD allelic ratio to define eligibility for Protocol #2487, as well as testing for FLT3-ITD allelic ratio. FLT3 and cKIT mutation studies in paired diagnostic and relapse samples, per protocol requirements. For the CAL101 trial, we will use IgH VDJ rearrangements to monitor disease burden as a measure of response. For Project 3. we will perform WTl expression studies for protocol #2498. on samples taken before, during, and at relapse, using flow cytometry to isolate AML blasts (via Core A). In addition, select samples will have single cell analyses performed to note the heterogeneity of WTl expression. Lastly, for protocol #2495 in Project 4, we will perform IgH VDJ and RORI expression to monitor disease burden and response, and perform gene expression analyses on pre- and relapsed samples to investigate pathways associated with resistance. These assays are integral to the aims of these protocols, and the assays are not available in commercial laboratories. The Radich Lab is a CAP/CLIA certified laboratory involved in studying the molecular genetics of leukemia and devising clinically useful tests more molecular diagnostics and monitoring. The lab has serviced as the North American molecular core for -10 CML industry trials, as well as the core of SWOG trials in ALL, CML, and AML, and as the central molecular core for the last and current COG AML trial, as well as establishing collaborations with biotechnology to develop new platforms for molecular diagnostics Cepheid, Fluidigm, and Nanostring.

Public Health Relevance

Molecular diagnostics are an important tool in understanding the biology of response, as well as providing an important and powerful tool in disease monitoring. The activities of Core B will help investigators more accurately measure the effectiveness of their therapeutic interventions, as well as help understand which patients become resistant to therapy, and why.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-GRB-T)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Fred Hutchinson Cancer Research Center
United States
Zip Code
Humbert, Olivier; Gisch, Don W; Wohlfahrt, Martin E et al. (2016) Development of Third-generation Cocal Envelope Producer Cell Lines for Robust Lentiviral Gene Transfer into Hematopoietic Stem Cells and T-cells. Mol Ther 24:1237-46
Mielcarek, Marco; Furlong, Terry; O'Donnell, Paul V et al. (2016) Posttransplantation cyclophosphamide for prevention of graft-versus-host disease after HLA-matched mobilized blood cell transplantation. Blood 127:1502-8
Achille, Nicholas J; Othus, Megan; Phelan, Kathleen et al. (2016) Association between early promoter-specific DNA methylation changes and outcome in older acute myeloid leukemia patients. Leuk Res 42:68-74
Cheng, Guang-Shing; Campbell, Angela P; Xie, Hu et al. (2016) Correlation and Agreement of Handheld Spirometry with Laboratory Spirometry in Allogeneic Hematopoietic Cell Transplant Recipients. Biol Blood Marrow Transplant 22:925-31
Festuccia, Moreno; Deeg, H Joachim; Gooley, Theodore A et al. (2016) Minimal Identifiable Disease and the Role of Conditioning Intensity in Hematopoietic Cell Transplantation for Myelodysplastic Syndrome and Acute Myelogenous Leukemia Evolving from Myelodysplastic Syndrome. Biol Blood Marrow Transplant 22:1227-33
Green, Margaret L; Leisenring, Wendy; Xie, Hu et al. (2016) Cytomegalovirus viral load and mortality after haemopoietic stem cell transplantation in the era of pre-emptive therapy: a retrospective cohort study. Lancet Haematol 3:e119-27
Sedlak, Ruth Hall; Hill, Joshua A; Nguyen, Thuy et al. (2016) Detection of Human Herpesvirus 6B (HHV-6B) Reactivation in Hematopoietic Cell Transplant Recipients with Inherited Chromosomally Integrated HHV-6A by Droplet Digital PCR. J Clin Microbiol 54:1223-7
Graf, Solomon A; Vaughn, Jennifer E; Chauncey, Thomas R et al. (2016) Comorbidities, Alcohol Use Disorder, and Age Predict Outcomes after Autologous Hematopoietic Cell Transplantation for Lymphoma. Biol Blood Marrow Transplant 22:1582-7
Aki, S Z; Inamoto, Y; Carpenter, P A et al. (2016) Confounding factors affecting the National Institutes of Health (NIH) chronic Graft-Versus-Host Disease Organ-Specific Score and global severity. Bone Marrow Transplant 51:1350-1353
Gallo, S; Woolfrey, A E; Burroughs, L M et al. (2016) Marrow grafts from HLA-identical siblings for severe aplastic anemia: does limiting the number of transplanted marrow cells reduce the risk of chronic GvHD? Bone Marrow Transplant 51:1573-1578

Showing the most recent 10 out of 1809 publications